Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib

BACKGROUND: Rechallenge with imatinib is an option in advanced gastrointestinal stromal tumor (GIST) patients following progression with standard tyrosine-kinase inhibitors (TKIs), imatinib, sunitinib and regorafenib. We retrospectively collected data from metastatic Italian GIST patients treated wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Vincenzi, Bruno, Nannini, Margherita, Badalamenti, Giuseppe, Grignani, Giovanni, Fumagalli, Elena, Gasperoni, Silvia, D’Ambrosio, Lorenzo, Incorvaia, Lorena, Stellato, Marco, Spalato Ceruso, Mariella, Napolitano, Andrea, Valeri, Sergio, Santini, Daniele, Tonini, Giuseppe, Casali, Paolo Giovanni, Dei Tos, Angelo Paolo, Pantaleo, Maria Abbondanza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116078/
https://www.ncbi.nlm.nih.gov/pubmed/30181783
http://dx.doi.org/10.1177/1758835918794623

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116078/
https://www.ncbi.nlm.nih.gov/pubmed/30181783
http://dx.doi.org/10.1177/1758835918794623

Ejemplares similares